The cost of haste: On drugs, vaccines and regulators

The cost of haste: On drugs, vaccines and regulators

Breach of ‘Do not harm’ principle

So far-reaching are the effects of COVID-19 that it has harried drug regulatory authorities, usually the most risk-averse within the bureaucracy.
‘Do no harm’ is the driving principle of drug regulation and this is reflected in the thicket of documents and permissions that stand before the average novel drug or vaccine, for a chance at making it to the market.

Compressed timelines

However, SARS-CoV-2, while mostly non-lethal, kills across demography and age-groups to confound sophisticated care systems.
This has sent a signal to drug companies, biomedical firms and governments to scramble for anything with even the slightest chance of success.
It is in this context that regulators, used to long timelines of testing new vaccines or drugs, are now under pressure to facilitate a solution rather than stick to weighing and dwelling on evidence of efficacy and safety.
India’s drug regulatory authority as well as the Department of Biotechnology, which also funds vaccine development and drug research, now collaborate on fast-tracking.
For instance, if an Indian company has partnered with a foreign one in developing a vaccine, then any trials already conducted by the foreign unit would be considered in allowing Indian companies to avoid repeating them in India.
For drugs, those that have been proven to be safe for treating one disease may skip a fresh, large human trial, or a phase-3 trial.
Potential vaccines too are now allowed to combine stages of trials — normally, regulators must approve results of each stage — to permit those testing the drug to move to the next stage.
The rush to compress timelines, in itself, is no guarantee that a workable vaccine or reliable drug will emerge any faster. Drugs and vaccine-development have historically been expensive because immunology is a complex, eternal struggle with disease, and with high failures.

Need of the hour

There have been instances when disease mortality is so high that not offering even a half-baked drug or a vaccine would be unethical.
That is a call regulators have to constantly take. But not all emergencies are the same.
There is now a situation, as in the case of itolizumab, a psoriasis drug repurposed for COVID-19, where the drug regulator has approved it for emergency use but the COVID-19 task force has expressed its reservations.
Such dissonance among experts is unacceptable especially when they all have access to the same evidence.
There is a tendency to view COVID-19 vaccine development or a new drug as a ‘race’ in which only the first vaccine to be out matters.

Haste does not aid science.

Source: TH

Join Our Telegram

AI Impact Summit 2026: IndiaAI Mission, MANAV Vision & Global AI Governance | UPSC GS-3 S&T

India’s Indo-Pacific Oceans Initiative (IPOI) – UPSC GS-2 Indo-Pacific Notes

20 Nov, 25
SHARE

India’s Indo-Pacific Oceans Initiative (IPOI) UPSC GS-2 INDO PACIFIC – IR/PSIR IPOI is India’s open, voluntary and non-treaty-based maritime initiative for building a free, open, inclusive and rules-based Indo-Pacific through practical cooperation. Why in News? India’s Indo-Pacific Oceans Initiative has gained renew

AI Impact Summit 2026: IndiaAI Mission, MANAV Vision & Global AI Governance | UPSC GS-3 S&T

19 May, 26
SHARE

AI Impact Summit 2026 UPSC GS-3 S&T PT-MAINS The India-AI Impact Summit 2026 positioned India as a Global South leader by shifting global AI debate from only AI safety and regulation to AI for development, inclusion and real-world impact. Why in News? India hosted the India-AI Impact Summit 2026 at B

Hong Kong Convention for Safe Ship Recycling – IMO Treaty & India’s Ship Recycling Law | UPSC GS-3 Environment

27 Jun, 25
SHARE

Hong Kong Convention for Safe Ship Recycling UPSC GS-3 ENVIRONMENT PT-MAINS The Hong Kong International Convention, 2009 is an IMO treaty that ensures ships are recycled safely without unnecessary risk to human health, worker safety and the environment. Why in News? The Hong Kong Convention entered into force on 26 June 2

LeadIT 2.0: India-Sweden Initiative for Low-Carbon Industry Transition | UPSC GS-2 & GS-3

14 Nov, 23
SHARE

LeadIT 2.0: Leadership Group for Industry Transition UPSC GS-2 IR GS-3 S&T LeadIT 2.0 is the second phase of the India-Sweden-led global initiative to support low-carbon transition in hard-to-abate industrial sectors. Why in News? The second phase of LeadIT was announced at the LeadIT Summit 2023, ho

India-EFTA TEPA: Trade & Economic Partnership Agreement Explained | UPSC GS-2 IR/PSIR

03 Sep, 25
SHARE

India-EFTA Trade and Economic Partnership Agreement UPSC GS-2 IR/PSIR The India-EFTA TEPA is a comprehensive trade pact between India and four non-EU European countries — Iceland, Liechtenstein, Norway and Switzerland — aimed at boosting trade, investment, jobs, services, technology and supply-chain resilience. Wh